FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults
"The entire Brand Institute and Drug Safety Institute Team congratulates Allergan on the FDA approval of VUITY," said Brand Institute's Chairman and CEO, James L. Dettore.
- "The entire Brand Institute and Drug Safety Institute Team congratulates Allergan on the FDA approval of VUITY," said Brand Institute's Chairman and CEO, James L. Dettore.
- "VUITY is truly a landmark treatment for those whose near vision has deteriorated.
- That we now know VUITY satisfies the rigorous safety and efficacy standards of the FDA is excellent news."
- "We believe the VUITY brand name has many desirable characteristics,including its brevity, tonality, and a prefix that evokes the word 'view'or the concept of vision," Dettore said.